Isomorphic Labs, an AI-powered drug discovery company spun out of Alphabet Inc.’s Google DeepMind, is in advanced discussions to raise more than $2 billion in a new round of funding, according to people familiar with the plan.
Thrive Capital, the venture firm that led Isomorphic Labs’ first funding round last year, is set to lead the new financing, said the people, who spoke on condition of anonymity as the information is not public. Alphabet is also participating, one person said, though the round is not yet closed.
